Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute pr
- PDF / 494,360 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 80 Downloads / 184 Views
CORRECTION
Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all‑trans retinoic acid and chemotherapy Hideho Henzan1 · Ken Takase2 · Tomohiko Kamimura3 · Yasuo Mori4 · Goichi Yoshimoto4 · Hiromi Iwasaki2 · Koji Nagafuji5 · Ryosuke Ogawa6 · Tetsuya Eto1 · Naoyuki Uchida7 · Tomoaki Fujisaki8 · Koji Kato4 · Mariko Minami2,4 · Yoshikane Kikushige4 · Koichi Akashi4 · Toshihiro Miyamoto4 · for the Fukuoka Blood & Marrow Transplantation Group (FBMTG)
© Japanese Society of Hematology 2020
Correction to: International Journal of Hematology https://doi.org/10.1007/s12185-020-02911-z
In the original publication of the article, the “CNS involvement” in the last row under the column “N = 50” has been published incorrectly. The correct Table 1 is given in this correction. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https://doi.org/10.1007/ s12185-020-02911-z. * Toshihiro Miyamoto [email protected]‑u.ac.jp 1
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
2
Department of Hematology, National Kyushu Medical Center, Fukuoka, Japan
3
Department of Hematology, Harasanshin Hospital, Fukuoka, Japan
4
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3‑1‑1 Maidashi, Higashi‑ku, Fukuoka 812‑8582, Japan
5
Department of Hematology, Kurume University Hospital, Kurume, Japan
6
Department of Hematology, Japan Community Health Care Organization Kyushu Hospital, Kita‑Kyushu, Japan
7
Department of Hematology, Toranomon Hospital, Tokyo, Japan
8
Department of Hematology, Matsuyama Red Cross Hospital, Ehime, Japan
13
Vol.:(0123456789)
H. Henzan et al.
Table 1 Background patient characteristics and summary of induction therapy Age (range), years Male/female WBC at diagnosis, × 109/L Platelet at diagnosis, × 109/L PML–RARA, × 105/μgRNA PT (range), sec, normal range 10–14 APTT (range), sec, normal range 24–39 DIC Yes No Additional cytogenetic abnormality Yes No CNS involvement Yes No
Total N = 50
Low risk (N = 27)
High risk (N = 23)
P
45 (18–65) 24/26 2.1 (0.2–97.8) 32 (6–170) 2.2 (0.21–42.0) 15.7 (8.0–89.9) 29.5 (21–281)
44 (18–65) 13/14 0.9 (0.2–2.3) 42 (6–170) 2.1 (0.21–28.0) 13.6 (11.2–89.9) 28.9 (22.8–120)
45 (19–63) 11/12 16.8 (3.6–97.8) 25 (11–74) 2.3 (0.21–42.0) 17.8 (8.0–71.8) 29.6 (21–281)
0.83* 1**
Data Loading...
